BioCentury
ARTICLE | Clinical News

Ryzodeg insulin degludec/insulin aspart regulatory update

July 11, 2016 7:00 AM UTC

EMA’s CHMP recommended expanding the label of Ryzodeg insulin degludec/insulin aspart from Novo Nordisk to treat Type I and Type II diabetes to include pediatric patients ages >=2. Ryzodeg is approved...